TCR signal strength defines distinct mechanisms of T cell dysfunction and cancer evasion
Mojdeh Shakiba(Memorial Sloan Kettering Cancer Center), Andrea Schietinger(Memorial Sloan Kettering Cancer Center), Sandra E. Carson(Cornell University), Friederike Dündar(Cornell University), Scott W. Lowe(Memorial Sloan Kettering Cancer Center), Francisco J. Sánchez‐Rivera(Howard Hughes Medical Institute), Matthew D. Hellmann(AstraZeneca (United States)), Paul Zumbo(Cornell University), Morgan Huse(Memorial Sloan Kettering Cancer Center), Nicholas D. Socci, Laura Menocal(Memorial Sloan Kettering Cancer Center), Mary Philip(Vanderbilt University), Vincent Reuter, Steven Camara(Memorial Sloan Kettering Cancer Center), Daniel K. Wells(Parker Institute for Cancer Immunotherapy), Emmanuel M. Bruno(Memorial Sloan Kettering Cancer Center), Richard P. Koche(Massachusetts General Hospital), Fella Tamzalit(American Association of Blood Banks), Doron Betel(Cornell University), Gabriel Espinosa-Carrasco(Inserm), Benjamin M. Whitlock(Kettering University), Nadine A. Defranoux(Parker Institute for Cancer Immunotherapy)
Cited by 153
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k